Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

Integrin-β1 Monoclonal Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Integrin (7) Apoptosis (1) Caspase (1) CD22 (1) Interleukin Related (1) NOD-like Receptor (NLR) (1)
By Research Areas:	Cancer (4) Inflammation/Immunology (4) Neurological Disease (3)

Inhibitors & Agonists

Inhibitory Antibodies

Targets Recommended: Integrin ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108831A

Natalizumab (Anti-CD49d) 3 Publications Verification AN100226; BG00002	Integrin	Inflammation/Immunology Cancer
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule *VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti*-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses ^[1] .

HY-108831

Natalizumab 3 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule *VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS*) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses ^[1] .

HY-P990781

Suciraslimab SM03	CD22 NOD-like Receptor (NLR) Interleukin Related Integrin	Neurological Disease Inflammation/Immunology
Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation ^[1]. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991652

MINT1526A RG-7594	Integrin	Cancer
MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research ^[1].

HY-P992055

Anti-ITGB1 Antibody AIIB2	Integrin Caspase Apoptosis	Neurological Disease Cancer
Anti-ITGB1 Antibody (AIIB2) is a monoclonal antibody targeting integrin-β1 (integrin-β1). Anti-ITGB1 Antibody blocks the binding of the *ITGB1* subunit to type I collagen ligands, and abrogates the adhesion of cancer cells to type I collagen-coated surfaces. Anti-ITGB1 Antibody inhibits the proliferation and induces apoptosis of human osteosarcoma cells by activating caspase-3 and regulating apoptosis-related proteins. Anti-ITGB1 Antibody is applicable to research related to osteosarcoma and medulloblastoma ^[1] .

HY-P992084

Anti-Integrin α5β1 Antibody	Integrin	Inflammation/Immunology
Anti-Integrin α5β1 Antibody is an anti-human monoclonal antibody targeting **integrin α5β1**.

HY-P992436

PAS-003	Integrin	Neurological Disease
PAS-003 is a humanized monoclonal antibody targerting α5β1 integrin. PAS-003 modulates immune cell migration, immune cell adhesion, improves behavior, and improves survival in ALS mouse models. PAS-003 can be used for the research of amyotrophic lateral sclerosis ^[1].

Cat. No.	Product Name	Target	Research Area	Image

HY-108831A

Natalizumab (Anti-CD49d) 3 Publications Verification AN100226; BG00002	Integrin	Inflammation/Immunology Cancer
Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule *VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti*-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses ^[1] .

HY-108831

Natalizumab 3 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule *VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS*) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses ^[1] .

HY-P990781

Suciraslimab SM03	CD22 NOD-like Receptor (NLR) Interleukin Related Integrin	Neurological Disease Inflammation/Immunology
Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation ^[1]. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991652

MINT1526A RG-7594	Integrin	Cancer
MINT1526A (RG-7594) is a humanized IgG1 monoclonal antibody inhibitor targeting α5β1 integrin. MINT1526A has significant anti-angiogenic activity. MINT1526A can be used for cancers research ^[1].

HY-P992055

Anti-ITGB1 Antibody AIIB2	Integrin Caspase Apoptosis	Neurological Disease Cancer
Anti-ITGB1 Antibody (AIIB2) is a monoclonal antibody targeting integrin-β1 (integrin-β1). Anti-ITGB1 Antibody blocks the binding of the *ITGB1* subunit to type I collagen ligands, and abrogates the adhesion of cancer cells to type I collagen-coated surfaces. Anti-ITGB1 Antibody inhibits the proliferation and induces apoptosis of human osteosarcoma cells by activating caspase-3 and regulating apoptosis-related proteins. Anti-ITGB1 Antibody is applicable to research related to osteosarcoma and medulloblastoma ^[1] .

HY-P992084

Anti-Integrin α5β1 Antibody	Integrin	Inflammation/Immunology
Anti-Integrin α5β1 Antibody is an anti-human monoclonal antibody targeting **integrin α5β1**.

HY-P992436

PAS-003	Integrin	Neurological Disease
PAS-003 is a humanized monoclonal antibody targerting α5β1 integrin. PAS-003 modulates immune cell migration, immune cell adhesion, improves behavior, and improves survival in ALS mouse models. PAS-003 can be used for the research of amyotrophic lateral sclerosis ^[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.